Body Composition and Fatty Liver Disease

Seoul National University

Status: Active, not recruiting

Conditions: Fatty Liver

Treatments: Diagnostic Test: Non-contrast low-dose abdomen CT; Diagnostic Test: bioelectrical impedance analysis (BIA); Diagnostic Test: Fibroscan

Study type: Interventional

Funder types: Other

Identifiers

NCT05695118

SNUH-2022-3238

Details and patient eligibility

About

This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.

Enrollment: 150 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• metabolic dysfunction-associated fatty liver disease (fatty liver with overweight/obesity, or type II DM or other metabolic dysfunction)
• or non-alcoholic fatty liver disease with liver function test abnormality
• signed informed consent

Exclusion criteria

• chronic hepatitis B or C
• other disease related to fatty liver such as glycogen storage disease, lipodystrophy, familial combined hyperlipidemia, hypobetalipoproteinemia, Weber-Christian syndrome or abetalipoproteinemia
• on medication related to hepatic steatosis (tamoxifen, steroid, valproic acid, methotrexate, amiodarone)
• diabetes after pancreatectomy
• history of total parenteral nutrition in 6 months
• pregnancy or nursing mother

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

150 participants in 1 patient group

non-contrast low-dose abdomen CT

Experimental group

Description:

non-contrast low-dose abdomen CT (target effective dose: \< 1.5 mSv). CT based body composition analysis is performedd with commercially available automatic segmentation software (DeepCatch, Medical IP, South Korea).

Treatment:

Diagnostic Test: Fibroscan

Diagnostic Test: bioelectrical impedance analysis (BIA)

Diagnostic Test: Non-contrast low-dose abdomen CT